Bionic eye progress revealed: How close are we to restore vision?

ONTARIO: A patient-focused webinar on Wednesday, September 10, 2025 (3–4 p.m. ET, Zoom) will unpack how modern “bionic eye” systems—also called visual or retinal prostheses—actually work, who may benefit, and why results vary. The session comes amid recurring headlines about breakthroughs, but real-world evidence shows cautious progress rather than instant restoration of normal sight.

What the bionic eye is—and isn’t

A bionic eye is an electrical implant paired with external components (typically glasses and a processor) that converts images into electrical pulses to stimulate remaining visual pathways. Most current systems target people who once had vision and now have severe loss from retinal degeneration such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). These devices can improve light perception and help users detect doors, curbs, or large shapes, but they do not recreate natural, high-resolution vision. Users must train their brains to interpret a “simulation of sight,” and outcomes vary.

Where implants sit and why that matters

Epiretinal systems sit on the surface of the retina and usually rely on an external camera. The Argus II was the best-known example in the US and Canada, but the original manufacturer stopped selling and broadly supporting it, highlighting the need for long-term service plans for implanted tech.

Subretinal systems place a microchip under the retina to tap into remaining retinal circuits. Europe has seen devices such as Alpha IMS/AMS, and newer photovoltaic implants like PRIMA are in feasibility studies for atrophic (dry) AMD with multi-year data showing safety and letter recognition improvements in small cohorts.

Suprachoroidal systems are positioned between the eye’s choroid and sclera. An Australian “second-generation” bionic eye reported meaningful functional gains over more than two years for four participants, adding to evidence for this approach.

Cortical systems bypass the eye entirely and stimulate the visual cortex. Efforts include the Gennaris platform from Monash Vision Group and Orion from Cortigent (formerly linked to Second Sight), which completed a six-year early feasibility study and holds FDA Breakthrough Device designation. These paths could help when the optic nerve or retina is too damaged for ocular implants.

This isn’t the first “world-first” claim—and that’s okay

Recent coverage has described a “world’s first” bionic eye from Australia’s Gennaris system (2024), and earlier animal studies in 2022 reported the Phoenix 99 retinal implant was safe in sheep, paving the way toward human trials. Such headlines underscore momentum, but they sit within a longer history that includes earlier marketed devices like Argus II and multiple parallel platforms now in trials. The field advances in increments: safety, durability, electrode counts, power and signal processing—all steps that steadily improve functional vision but stop short of natural sight.

Why the webinar matters for patients and families

The upcoming session promises plain-language guidance on candidacy (for example, needing an intact visual cortex and, often, a healthy optic nerve), realistic goals (orientation, navigation, object detection rather than fine print), and device trade-offs (external cameras vs on-chip sensing, surgical complexity, service and support). It also arrives at a time when long-term follow-up, repair pathways, and company viability are front-of-mind for implant recipients and clinicians alike.

Key takeaways at a glance

• Bionic eye systems can restore useful visual sensations, but not natural vision.
• Multiple designs exist—epiretinal, subretinal, suprachoroidal, and cortical—each with strengths and limits.
• Evidence is growing: European approvals have existed for select subretinal systems, Australian teams report multi-year functional gains, and cortical devices are in early feasibility stages.
• Support and lifecycle planning for implants are critical lessons from past programs like Argus II.

Event details

• Webinar: Understanding the bionic eye and retinal prostheses
• Date and time: Wednesday, September 10, 2025, 3–4 p.m. ET
• Zoom link: CLICK HERE TO REGISTER

Bottom line

Bionic vision is moving forward, but carefully. For people with advanced retinal disease or other causes of profound blindness, today’s devices can offer meaningful function—detecting light, movement, and simple shapes—while next-generation retinal and cortical implants aim to widen fields of view, sharpen perception, and improve usability. The science is real, the progress is incremental, and informed expectations are essential.

Stay updated with Medical News Pakistan

CLICK HERE TO JOIN Medical News WhatsApp community to get the latest updates on global health guidelines, medical research, and expert insights directly on your phone.